Drug intelligence / Profile preview

VTK-211

Development stage: Preclinical
Lead developer: Vitarka Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

VTK-211 is a preclinical-stage pan-KRAS protein degrader being developed by Vitarka Therapeutics. It is designed to target and degrade multiple isoforms of the KRAS protein, which is a common driver in various cancers. The drug is specifically being investigated for the treatment of early breast cancer (EBC) and estrogen receptor alpha (ERα)-positive solid tumors. By utilizing a targeted protein degradation approach, VTK-211 aims to overcome the limitations of traditional KRAS inhibitors, potentially offering a more comprehensive therapeutic effect against KRAS-driven malignancies.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on VTK-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTK-211.

Explore the full profile